Safer, Smarter Cell Therapies With AI

In this segment of Cell & Gene Live, "Building Smarter Cell Therapies with AI and Synthetic Biology," Claire Aldridge, Ph.D., shared why the most compelling AI and synthetic biology strategies are those built on proprietary, well annotated experimental data that continuously train and validate models. Senti Biosciences' Tim Lu, M.D., Ph.D. described how logic gated designs and AI enabled control of selectivity, dose, and tissue targeting are already improving the therapeutic window in programs, such as SENTI 202, with early AML data suggesting these approaches could soon enter routine clinical use.